AMP 2025 Annual Meeting

This workshop will examine how next day automated NGS technology is being leveraged to accelerate genomic profiling in myeloid malignancies research—helping to support timely insights. The workshop will also highlight the use of the Oncomine™ TCR Pan-Clonality Assay for evaluating immune repertoires in T-cell lymphoma samples, with applications in clonality assessment and detection of measurable residual disease (MRD). Discussions will emphasize how these approaches align with current testing frameworks and expand the utility of NGS in hematologic research.

Speakers:
Kritika Krishnamurthy, MD, Montefiore Medical Center
Mohamed H. Maher, Ph.D., Pharm.D. MD Anderson Cancer Center

Room: 153A, Level 1

EGFR exon 20 insertions in non-small cell lung cancer (NSCLC) are clinically important but challenging biomarkers to detect rapidly and accurately. Rapid, broad testing is essential to identify these alterations and guide targeted treatment. The Oncomine Dx Express Test is a next‑generation sequencing (NGS) in vitro diagnostic (IVD) that delivers results from tissue to report in as little as 24 hours, as a companion diagnostic (CDx) for EGFR exon 20 insertions in NSCLC and tumor profiling across multiple solid tumors. The test detects a broad spectrum of alterations—including heterogeneous EGFR exon 20 insertions—and its automated workflow minimizes hands‑on time and bioinformatics burden, enabling adoption in diverse laboratory settings. Hear testing strategies, validation data, and practical implementation of rapid NGS to support timely therapy decisions.

Speakers:
David Chi, Thermo Fisher Scientific
Angie Cheng, Thermo Fisher Scientific
Steve Stone, Argent Global Services

Room: 153A, Level 1

This workshop features initial experiences with the Oncomine Comprehensive Assay Plus on the Genexus System for next-day comprehensive genomic profiling (CGP) results. This complete, end-to-end CGP solution detects a broad range of genomic alterations across 517 genes, including single-nucleotide variants (SNVs), insertions and deletions (indels), copy number variations (CNVs), and fusions. Additionally, the assay detects genomic signatures such as homologous recombination deficiency (HRD), tumor mutational burden (TMB), and microsatellite instability (MSI). Hear how labs can benefit from this easy, automated, and complete solution.

Speaker:
Elaine Wong-Ho, PhD, Thermo Fisher Scientific
Andrew Campbell, PhD, Geisinger Medical Laboratories

Room: 153A, Level 1

Join Dr. Peter H. O'Donnell from University of Chicago for an engaging workshop on the transformative role of pharmacogenomics (PGx) in oncology. Explore how questions of clinical validity of PGx can be investigated through clinical trials focused on patient outcomes and the net-effect of personalized medicine in cancer treatment. This session will delve into the importance of PGx in optimizing therapeutic strategies, reducing adverse drug reactions, and improving patient care. Ideal for clinical labs and healthcare professionals, this workshop offers valuable insights into the future of oncology and the critical role of PGx in advancing precision medicine. Don't miss this opportunity to enhance your understanding and application of PGx in oncology.

Speaker:
Peter H. O'Donnell, MD University of Chicago

Room: 153A, Level 1

Analysis of liquid biopsy samples using digital PCR (dPCR) has been proposed to provide fast, accurate, and robust results with high sensitivity. Efficient and accurate sample preparation and analysis helps to play a crucial role in cancer research and optimizing workflows. This presentation will explore the benefits of streamlined, scalable workflows for sample processing and dPCR analysis. We highlight how a simplified dPCR workflow, with throughput flexibility, multiplex capability, and fast turnaround time can support simultaneous detection of mutations with high sensitivity and low false positives, helping to offer an advantage liquid biopsy cancer research.

Speaker:
Clarence Lee, Thermo Fisher Scientific

Room: 153A, Level 1

Join Michael Howard, Project Specialist at LabCorp Cytogenetics, as he shares research on optimizing molecular applications using advanced automation and chemistry. His presentation explores ways to enhance productivity, precision, and sample versatility in molecular cytogenetic workflows. With growing demands for high throughput across diverse sample types—such as cell cultures, tissues, amniotic fluid, and whole blood—Michael will highlight innovative methods to streamline processes and improve nucleic acid quality. He will also address challenges like inhibitory preservatives (e.g., heparin) and demonstrate how scalable automation and refined chemistry can meet the evolving needs of women’s health and genetics. Attendees will gain valuable insights to help position their laboratories at the forefront of molecular cytogenetic innovation and clinical implementation.

Speaker:
Michael Howard, LabCorp Cytogenetics

Room: 153A, Level 1